Unicycive Therapeutics, Inc. (UNCY) stock
UNCYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.57−0.13 (-3.51%)
Close on Nov 18, 2026Market cap $99.44MP/E –Yield –
Unicycive Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Unicycive Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$27.84M. For fiscal 2025 it was -$31.32M. The highest annual figure on record is -$1.46M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$31.32M | – |
| FY2024 | Dec 31, 2024 | -$28.58M | – |
| FY2023 | Dec 31, 2023 | -$18.28M | – |
| FY2022 | Dec 31, 2022 | -$15.65M | – |
| FY2021 | Dec 31, 2021 | -$5.77M | – |
| FY2020 | Dec 31, 2020 | -$1.46M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.60M | – |
| Q1 FY2026 | Mar 31, 2026 | -$6.24M | – |
| Q4 FY2025 | Dec 31, 2025 | -$8.03M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.96M | – |
| Q2 FY2025 | Jun 30, 2025 | -$8.42M | – |
| Q1 FY2025 | Mar 31, 2025 | -$8.90M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.55M | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.25M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.32M | – |
| Q1 FY2024 | Mar 31, 2024 | -$6.46M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.44M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.42M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.50M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.92M | – |
| Q4 FY2022 | Dec 31, 2022 | -$6.08M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.56M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.05M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.96M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.40M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.47M | – |
| Q2 FY2021 | Jun 30, 2021 | -$217.00K | – |
| Q1 FY2021 | Mar 31, 2021 | -$673.00K | – |
| Q4 FY2020 | Dec 31, 2020 | -$538.00K | – |
| Q3 FY2020 | Sep 30, 2020 | -$706.00K | – |
See a number that looks wrong?